234 related articles for article (PubMed ID: 15284265)
1. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions.
Hoang-Xuan K; Capelle L; Kujas M; Taillibert S; Duffau H; Lejeune J; Polivka M; Crinière E; Marie Y; Mokhtari K; Carpentier AF; Laigle F; Simon JM; Cornu P; Broët P; Sanson M; Delattre JY
J Clin Oncol; 2004 Aug; 22(15):3133-8. PubMed ID: 15284265
[TBL] [Abstract][Full Text] [Related]
2. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.
Levin N; Lavon I; Zelikovitsh B; Fuchs D; Bokstein F; Fellig Y; Siegal T
Cancer; 2006 Apr; 106(8):1759-65. PubMed ID: 16541434
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
Kaloshi G; Benouaich-Amiel A; Diakite F; Taillibert S; Lejeune J; Laigle-Donadey F; Renard MA; Iraqi W; Idbaih A; Paris S; Capelle L; Duffau H; Cornu P; Simon JM; Mokhtari K; Polivka M; Omuro A; Carpentier A; Sanson M; Delattre JY; Hoang-Xuan K
Neurology; 2007 May; 68(21):1831-6. PubMed ID: 17515545
[TBL] [Abstract][Full Text] [Related]
4. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
Brandes AA; Tosoni A; Cavallo G; Reni M; Franceschi E; Bonaldi L; Bertorelle R; Gardiman M; Ghimenton C; Iuzzolino P; Pession A; Blatt V; Ermani M;
J Clin Oncol; 2006 Oct; 24(29):4746-53. PubMed ID: 16954518
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
Ahluwalia MS; Xie H; Dahiya S; Hashemi-Sadraei N; Schiff D; Fisher PG; Chamberlain MC; Pannullo S; Newton HB; Brewer C; Wood L; Prayson R; Elson P; Peereboom DM
J Neurooncol; 2015 Mar; 122(1):111-9. PubMed ID: 25534576
[TBL] [Abstract][Full Text] [Related]
6. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Kouwenhoven MC; Kros JM; French PJ; Biemond-ter Stege EM; Graveland WJ; Taphoorn MJ; Brandes AA; van den Bent MJ
Eur J Cancer; 2006 Oct; 42(15):2499-503. PubMed ID: 16914310
[TBL] [Abstract][Full Text] [Related]
7. Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results.
Chahlavi A; Kanner A; Peereboom D; Staugaitis SM; Elson P; Barnett G
J Neurooncol; 2003 Feb; 61(3):267-73. PubMed ID: 12675321
[TBL] [Abstract][Full Text] [Related]
8. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
9. Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity.
Thiessen B; Maguire JA; McNeil K; Huntsman D; Martin MA; Horsman D
J Neurooncol; 2003 Sep; 64(3):271-8. PubMed ID: 14558604
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors.
Gan HK; Rosenthal MA; Dowling A; Kalnins R; Algar E; Wong N; Benson A; Woods AM; Cher L
Neuro Oncol; 2010 May; 12(5):500-7. PubMed ID: 20406900
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial.
Taliansky-Aronov A; Bokstein F; Lavon I; Siegal T
J Neurooncol; 2006 Sep; 79(2):153-7. PubMed ID: 16855865
[TBL] [Abstract][Full Text] [Related]
12. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.
Hashimoto N; Murakami M; Takahashi Y; Fujimoto M; Inazawa J; Mineura K
Cancer; 2003 May; 97(9):2254-61. PubMed ID: 12712480
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.
Buckner JC; Gesme D; O'Fallon JR; Hammack JE; Stafford S; Brown PD; Hawkins R; Scheithauer BW; Erickson BJ; Levitt R; Shaw EG; Jenkins R
J Clin Oncol; 2003 Jan; 21(2):251-5. PubMed ID: 12525516
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma.
Mikkelsen T; Doyle T; Anderson J; Margolis J; Paleologos N; Gutierrez J; Croteau D; Hasselbach L; Avedissian R; Schultz L
J Neurooncol; 2009 Mar; 92(1):57-63. PubMed ID: 19011763
[TBL] [Abstract][Full Text] [Related]
15. First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.
Taal W; Dubbink HJ; Zonnenberg CB; Zonnenberg BA; Postma TJ; Gijtenbeek JM; Boogerd W; Groenendijk FH; Kros JM; Kouwenhoven MC; van Marion R; van Heuvel I; van der Holt B; Bromberg JE; Sillevis Smitt PA; Dinjens WN; van den Bent MJ;
Neuro Oncol; 2011 Feb; 13(2):235-41. PubMed ID: 21177338
[TBL] [Abstract][Full Text] [Related]
16. Response of low-grade oligodendroglial tumors to temozolomide.
Byrne TN
J Neurooncol; 2004 Dec; 70(3):279-80. PubMed ID: 15662968
[No Abstract] [Full Text] [Related]
17. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.
Vogelbaum MA; Berkey B; Peereboom D; Macdonald D; Giannini C; Suh JH; Jenkins R; Herman J; Brown P; Blumenthal DT; Biggs C; Schultz C; Mehta M
Neuro Oncol; 2009 Apr; 11(2):167-75. PubMed ID: 18779504
[TBL] [Abstract][Full Text] [Related]
19. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.
Triebels VH; Taphoorn MJ; Brandes AA; Menten J; Frenay M; Tosoni A; Kros JM; Stege EB; Enting RH; Allgeier A; van Heuvel I; van den Bent MJ
Neurology; 2004 Sep; 63(5):904-6. PubMed ID: 15365146
[TBL] [Abstract][Full Text] [Related]
20. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
Xiong J; Liu Y; Wang Y; Ke RH; Mao Y; Ye ZR
Chin Med J (Engl); 2010 Dec; 123(24):3566-73. PubMed ID: 22166632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]